Policy | February 02, 2024
Industry’s reaction to Union Budget 2024-25
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The new campus has been designed as an employee-centred experience and ecosystem zone
An accomplished R&D leader and champion of the application of AI to drug discovery
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Subscribe To Our Newsletter & Stay Updated
